AZN AstraZeneca PLC ADR

USD 78.88 0.32 0.407332
Icon

AstraZeneca PLC ADR (AZN) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - General | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 78.88

+0.32 (+0.41)%

USD 245.11B

4.99M

USD 83.17(+5.43%)

USD 58.71 (-25.57%)

Icon

AZN

AstraZeneca PLC ADR (USD)
COMMON STOCK | NSD
USD 78.88
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 245.11B

USD 58.71 (-25.57%)

USD 78.88

AstraZeneca PLC ADR (AZN) Stock Forecast

USD 83.17
(+5.43%)

Based on the AstraZeneca PLC ADR stock forecast from 5 analysts, the average analyst target price for AstraZeneca PLC ADR is USD 83.17 over the next 12 months. AstraZeneca PLC ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AstraZeneca PLC ADR is Slightly Bullish , which is based on 11 positive signals and 5 negative signals. At the last closing, AstraZeneca PLC ADR’s stock price was USD 78.88. AstraZeneca PLC ADR’s stock price has changed by -0.89% over the past week, -0.38% over the past month and +7.50% over the last year.

No recent analyst target price found for AstraZeneca PLC ADR
No recent average analyst rating found for AstraZeneca PLC ADR

Company Overview AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga...Read More

https://www.astrazeneca.com

1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA

89,900

December

USD

USA

Adjusted Closing Price for AstraZeneca PLC ADR (AZN)

Loading...

Unadjusted Closing Price for AstraZeneca PLC ADR (AZN)

Loading...

Share Trading Volume for AstraZeneca PLC ADR Shares

Loading...

Compare Performance of AstraZeneca PLC ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AZN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To AstraZeneca PLC ADR (Sector: Drug Manufacturers - General )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AMGN
Amgen Inc -1.73 (-0.56%) USD166.24B 44.27 13.31

ETFs Containing AZN

Symbol Name AZN's Weight Expense Ratio Price(Change) Market Cap
XSDR:LSE
Xtrackers MSCI Europe Hea.. 15.01 % 0.17 % -25.00 (-0.12%) USD0.16B

Frequently Asked Questions About AstraZeneca PLC ADR (AZN) Stock

Based on ratings from 5 analysts AstraZeneca PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, sell and 1 hold ratings.

AZN stock's dividend yield is 1.85%. Our analysis grades AZN stock's dividend yield at F. This means that AZN stock's dividend yield is above 25% of the stocks in the Drug Manufacturers - General sector in the NSD exchange. Based on this AZN may be a poor dividend stock for its sector.

Based on targets from 5 analysts, the average taret price for AZN is USD 83.17 over the next 12 months. The maximum analyst target price is USD 97 while the minimum anlayst target price is USD 70.

AZN stock's Price/Earning ratio is 38.94. Our analysis grades AZN stock's Price / Earning ratio at C-. This means that AZN stock's Price/Earning ratio is above 29% of the stocks in the Drug Manufacturers - General sector in the NSD exchange. Based on this AZN may be undervalued for its sector.

The last closing price of AZN's stock was USD 78.88.

The most recent market capitalization for AZN is USD 245.11B.

Based on targets from 5 analysts, the average taret price for AZN is projected at USD 83.17 over the next 12 months. This means that AZN's stock price may go up by +5.43% over the next 12 months.

Following are ETFs with the highest allocation to AstraZeneca PLC ADR's stock :

XSDR:LSE

As per our most recent records AstraZeneca PLC ADR has 89,900 Employees.

AstraZeneca PLC ADR's registered address is 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA. You can get more information about it from AstraZeneca PLC ADR's website at https://www.astrazeneca.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...